Vulvovaginal Candidiasis
Pipeline by Development Stage
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (6)
Total enrollment: 580 patients across 6 trials
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.